debio 0123
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 14, 2019 (NCT03968653)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Serine/threonine-protein kinase WEE1INHIBITOR
WEE1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05815160 | Phase 1 | May 2, 2023 | Debiopharm |
| NCT05765812 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2023 | Debiopharm |
| NCT05109975 | Phase 1 | Nov 30, 2021 | Debiopharm |
| NCT03968653 | Phase 1 | Jul 14, 2019 | Debiopharm |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Debiopharm | For profit | 4 | 4 | 2 | 2019 |
1 organizations
Page 1 / 1